TPD & Induced Proximity Summit Leaderboard
  • Monday, June 15, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist

Author

Pharma Journalist 8869 posts 0 comments

Chiesi Completes KalVista Acquisition, Expands Rare Disease Portfolio

Jun 12, 2026
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking a significant expansion of its rare diseases business and adding a recently approved hereditary…
Read More...

IMAAVY Shows Strong Results in Rare Blood Disorder Trial

Jun 12, 2026
Johnson & Johnson has reported positive results from the Phase 2/3 ENERGY study evaluating IMAAVY® (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a…
Read More...

GSK’s Momelotinib Gains Orphan Status for VEXAS Syndrome

Jun 12, 2026
GSK has received a significant regulatory boost for its investigational efforts in rare diseases after both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency…
Read More...

FDA Grants Priority Review for Tecentriq in Colon Cancer

Jun 12, 2026
Roche has moved a step closer to expanding the use of its immunotherapy Tecentriq® (atezolizumab) in early-stage colon cancer after the U.S. Food and Drug Administration (FDA) accepted…
Read More...

China Approves Akeso’s Gumokimab for Plaque Psoriasis

Jun 12, 2026
Akeso has secured regulatory approval in China for gumokimab (AK111), its internally developed anti-IL-17 monoclonal antibody, for the treatment of adults with moderate-to-severe plaque…
Read More...

Parabilis Raises $845 Million Through IPO and Private Placement

Jun 12, 2026
Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company focused on developing therapies against historically difficult-to-target disease-driving proteins, has successfully…
Read More...

XtalPi Lands $400 Million AI Drug Discovery Partnership

Jun 12, 2026
XtalPi has entered into a strategic collaboration with a leading international biopharmaceutical company to develop a next-generation small-molecule therapy targeting a complex G…
Read More...

UK Approves First Oral Wegovy for Weight Management

Jun 12, 2026
The United Kingdom has become the first country in Europe to approve Wegovy® pill (semaglutide tablets) for weight management, providing adults living with obesity or overweight a new…
Read More...

DePuy Synthes Launches AI-Powered Hip Navigation System

Jun 11, 2026
DePuy Synthes, a leader in orthopedic technologies and part of Johnson & Johnson MedTech, has announced the U.S. commercial launch of VELYS™ Hip Navigation with AI Assistance, a…
Read More...

Shaquille O’Neal Highlights Sleep Apnea Treatment With Zepbound

Jun 11, 2026
Eli Lilly and Company has launched a new national awareness campaign featuring basketball legend Shaquille O’Neal to spotlight moderate-to-severe obstructive sleep apnea (OSA), a common…
Read More...
Prev Next
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
5th World ADC Summit South Korea
World TPD & Induced Proximity Summit South Korea
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Chiesi Completes KalVista Acquisition, Expands Rare Disease Portfolio
  • IMAAVY Shows Strong Results in Rare Blood Disorder Trial
  • GSK’s Momelotinib Gains Orphan Status for VEXAS Syndrome
  • FDA Grants Priority Review for Tecentriq in Colon Cancer
  • China Approves Akeso’s Gumokimab for Plaque Psoriasis

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.